That’s all we think about

We are a consortium of companies who work together to find, fund and develop bioscience discoveries into life-changing medical innovations – and take them to the people who need them most.

Our scientific team identifies scientific discoveries from laboratories all over the world that have the potential to have life-changing impact.
Our corporate advisory and investment banking teams work together to translate scientific milestones into value creation events, creating financial instruments and corporate structures that activate commercial value.
Our commercialization team partners with healthcare providers and unlocks regulatory pathways to take the discovery to the people who need it.

The story so far


GBS Inc. Nasdaq IPO
OncoTEX team publishes landmark OxaliTEX preclinical trial findings in Proceedings of the National Academy of Sciences (PNAS).
iQNovate Ltd (NSX:IQN) name change to The iQ Group Global Ltd (NSX:IQG)


The iQ Group Global acquires TEX Core, an oncology drug platform
Recognised as one of Australia and New Zealand’s Top 5 Most Innovative Companies by The Australian Financial Review and BOSS Magazine
FarmaForce wins Sales Team of the Year at PRIME Awards for the third time
Capital Labs raises more than $828,000 for healthcare startup


China patent granted for Saliva Glucose Biosensor
FarmaForce wins Sales Team of the Year at PRIME Awards for the second time


US patent granted for Saliva Glucose Biosensor


The iQ Group Global accelerated the development of the Saliva Glucose Biosensor
iQ Capital incorporated in the USA
Series 8 Fund launched
FarmaForce wins Sales Team of the Year at PRIME Awards


iQ3 ASX listed
FarmaForce ASX listed


Inception of CRC and FarmaForce


iQX lists on NSX
iQ3 inception
OTFT-based saliva glucose biosensor invented by Professor Dastoor and team. IP filed in March


iQnovate commences trading in the USA


iQnovate lists on NSX
iQX inception


Inception of iQnovate

Our Collaborators

Meet the people bringing our technology to life